Latest filing published 18 Dec 2024 for NRX Pharmaceuticals, Inc., €44k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +55.9%Entry US$1.52 · Close at T+365 US$2.37
- -40.9%Entry US$3.20 · Close at T+365 US$1.89
- -38.8%Entry US$3.40 · Close at T+365 US$2.08
- -11.3%Entry US$7.35 · Close at T+365 US$6.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jonathan C. Javitt: trading record in brief
Jonathan C. Javitt is a declared insider at 2 companies (chief executive); the most frequent names are NRX Pharmaceuticals, Inc. and Brainstorm Cell Therapeutics Inc. Over a trading history stretching from 27 August 2008 to 17 December 2024, the count stands at 12 filings.
Both buying and selling appear: 5 purchases worth €5.6M, against 2 sales worth €389k. On balance, insiders were net buyers of €5.2M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 4 share grants. In 2024 alone, the filings show 1 purchase and no sales.
The median purchase comes to €54k. The 5 purchases reviewed show no overlap with other insiders buying the same stock within a month. For 5 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 20% of cases, with a median move of -9.5%. These figures describe past trades and do not predict future prices.
The latest filing, published on 18 December 2024, reports an open-market purchase of €44k in NRX Pharmaceuticals, Inc. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Jonathan C. Javitt
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 40,000 shares@ US$1.170.7% of flowCommon StockSEC:0001415889-24-029694:0Canonical exit: 17 Mar 2025 (T+90)
- 100,000 shares@ US$0.330.5% of flowCommon StockSEC:0001104659-23-094815:0Canonical exit: 21 Nov 2023 (T+90)
- 200,000 shares@ US$0.3221.0% of flowCommon StockSEC:0001104659-23-094406:0Canonical exit: 20 Nov 2023 (T+90)
- 400,000 shares@ US$1.006.4% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012324:0
- 100,000 shares@ US$58.0090.5% of flowCommon StockSEC:0000921895-22-001872:0Canonical exit: 30 Aug 2022 (T+90)
- 100,000 shares@ US$0.580.9% of flowCommon StockSEC:0000921895-22-001874:0Canonical exit: 30 Aug 2022 (T+90)
- 13,348,997 sharesCommon StockSEC:0000950142-21-001945:1
- 1,422,000 sharesCommon StockSEC:0000950142-21-001945:2
- 46,332 sharesCommon StockSEC:0000950142-21-001945:0
- 0Common StockSEC:0001144204-09-012412:0
- 1,000,000 shares@ US$0.01Common StockSEC:0001181431-08-050620:0
- 40,000 shares@ US$0.25Common StockSEC:0001181431-08-050620:1
12 of 12 declarations